Skip to content
AiONAiON
Medical directoryActive ingredient

Androxal (enclomifene)

Name under which enclomifene was developed in the United States. The FDA never approved it: the company received complete response letters and the final rejection came around the end of 2015; clinical development was discontinued for all indications in April 2021.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.